Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization

In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A t...

Descripción completa

Detalles Bibliográficos
Autores principales: Betschel, Stephen D., Warrington, Richard J., Schellenberg, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962395/
https://www.ncbi.nlm.nih.gov/pubmed/27468299
http://dx.doi.org/10.1186/s13223-016-0138-9
_version_ 1782444826286882816
author Betschel, Stephen D.
Warrington, Richard J.
Schellenberg, Robert
author_facet Betschel, Stephen D.
Warrington, Richard J.
Schellenberg, Robert
author_sort Betschel, Stephen D.
collection PubMed
description In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam’s utilization was classified as appropriate based on Canadian IVIg guidelines.
format Online
Article
Text
id pubmed-4962395
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49623952016-07-28 Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization Betschel, Stephen D. Warrington, Richard J. Schellenberg, Robert Allergy Asthma Clin Immunol Review In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam’s utilization was classified as appropriate based on Canadian IVIg guidelines. BioMed Central 2016-07-27 /pmc/articles/PMC4962395/ /pubmed/27468299 http://dx.doi.org/10.1186/s13223-016-0138-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Betschel, Stephen D.
Warrington, Richard J.
Schellenberg, Robert
Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title_full Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title_fullStr Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title_full_unstemmed Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title_short Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
title_sort clinical experience with octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a canadian retrospective review of utilization
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962395/
https://www.ncbi.nlm.nih.gov/pubmed/27468299
http://dx.doi.org/10.1186/s13223-016-0138-9
work_keys_str_mv AT betschelstephend clinicalexperiencewithoctagam10asolventdetergentvirusinactivatedintravenousimmunoglobulinacanadianretrospectivereviewofutilization
AT warringtonrichardj clinicalexperiencewithoctagam10asolventdetergentvirusinactivatedintravenousimmunoglobulinacanadianretrospectivereviewofutilization
AT schellenbergrobert clinicalexperiencewithoctagam10asolventdetergentvirusinactivatedintravenousimmunoglobulinacanadianretrospectivereviewofutilization

Ejemplares similares